1. Home
  2. ONDS vs ADPT Comparison

ONDS vs ADPT Comparison

Compare ONDS & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ondas Holdings Inc.

ONDS

Ondas Holdings Inc.

HOLD

Current Price

$7.60

Market Cap

5.6B

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$29.57

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONDS
ADPT
Founded
2014
2009
Country
United States
United States
Employees
N/A
624
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
4.5B
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
ONDS
ADPT
Price
$7.60
$29.57
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
9
Target Price
★ $19.83
$17.78
AVG Volume (30 Days)
★ 54.4M
1.9M
Earning Date
05-15-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 63.89
EPS
★ 0.38
N/A
Revenue
$50,731,000.00
★ $276,976,000.00
Revenue This Year
$662.14
$3.98
Revenue Next Year
$76.37
$22.72
P/E Ratio
$19.50
★ N/A
Revenue Growth
★ 605.31
54.77
52 Week Low
$4.95
$12.00
52 Week High
$15.28
$28.78

Technical Indicators

Market Signals
Indicator
ONDS
ADPT
Relative Strength Index (RSI) 42.73 64.41
Support Level $6.92 $23.73
Resistance Level $8.58 N/A
Average True Range (ATR) 0.31 1.08
MACD 0.03 0.19
Stochastic Oscillator 30.29 79.81

Price Performance

Historical Comparison
ONDS
ADPT

About ONDS Ondas Holdings Inc.

Ondas Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system. Geographically, the company operates in Israel, Germany, United Arab Emirates, United States, and Other Countries. It derives maximum revenue from Israel.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: